News Related to Healthcare Royalty Partners

Related coverage linked through entity extraction aliases.

GENFIT to Receive $20M Milestone as Iqirvo 2025 Sales Top $200M

Apr 27, 2026

GENFIT will receive a $20 million milestone from Ipsen after Iqirvo posted $208 million in 2025 net sales in primary biliary cholangitis. The sales also triggered a €30 million instalment under GENFIT’s royalty-financing deal.

Atara Biotherapeutics Schedules FDA Meeting on Tabelecleucel Application

Mar 12, 2026

Atara Biotherapeutics announced a Type A meeting with the FDA to discuss the Complete Response Letter for tabelecleucel's Biologics License Application, held by partner Pierre Fabre Pharmaceuticals.